Abatacept, a CTLA-4–Ig fusion protein that blocks the CD28-mediated costimulatory signal necessary for T-cell activation, has been tested in phase I clinical trials for several autoimmune diseases. This evidence concerns the gene CTLA4 and autoimmune disease.